223 related articles for article (PubMed ID: 22119012)
1. Preparation of blood products for transfusion: is there a best method?
Devine DV; Serrano K
Biologicals; 2012 May; 40(3):187-90. PubMed ID: 22119012
[TBL] [Abstract][Full Text] [Related]
2. Update on pathogen reduction technology for therapeutic plasma: an overview.
Solheim BG; Seghatchian J
Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
[TBL] [Abstract][Full Text] [Related]
3. The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets.
Vamvakas EC
Clin Lab; 2010; 56(7-8):263-79. PubMed ID: 20857891
[TBL] [Abstract][Full Text] [Related]
4. Safety of donating multiple products in a single apheresis collection: are we expecting too much?
Strauss RG
J Clin Apher; 2003; 18(3):135-40. PubMed ID: 14569607
[TBL] [Abstract][Full Text] [Related]
5. Platelet activation of platelet concentrates derived from buffy coat and apheresis methods.
Ali SF
Transfus Apher Sci; 2011 Feb; 44(1):11-3. PubMed ID: 21277261
[TBL] [Abstract][Full Text] [Related]
6. Pathogen reduction of blood components.
Solheim BG
Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
[TBL] [Abstract][Full Text] [Related]
7. Universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions.
Pruss A; Kalus U; Radtke H; Koscielny J; Baumann-Baretti B; Balzer D; Dörner T; Salama A; Kiesewetter H
Transfus Apher Sci; 2004 Feb; 30(1):41-6. PubMed ID: 14746820
[TBL] [Abstract][Full Text] [Related]
8. Transfusion reactions: a comparative observational study of blood components produced before and after implementation of semiautomated production from whole blood.
Semple E; Bowes-Schmidt A; Yi QL; Shimla S; Devine DV
Transfusion; 2012 Dec; 52(12):2683-91. PubMed ID: 22738255
[TBL] [Abstract][Full Text] [Related]
9. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis.
Vasconcelos E; Figueiredo AC; Seghatchian J
Transfus Apher Sci; 2003 Aug; 29(1):13-6. PubMed ID: 12877887
[TBL] [Abstract][Full Text] [Related]
10. Plasma and cryoprecipitate manufactured from whole blood held overnight at room temperature meet quality standards.
Serrano K; Scammell K; Weiss S; Culibrk B; Levin E; Gyöngyössy-Issa M; Devine DV
Transfusion; 2010 Feb; 50(2):344-53. PubMed ID: 19843287
[TBL] [Abstract][Full Text] [Related]
11. [Preparation of pooled granulocytes concentrates from whole blood buffy coats (PGC) as an alternative to apheresis].
Mastronardi R; Cleophax S; Begué S; Hurtado-Nedelec M; Gross S; Bocquet T; Djoudi R
Transfus Clin Biol; 2019 Sep; 26(3):164-170. PubMed ID: 31400933
[TBL] [Abstract][Full Text] [Related]
12. Markers of platelet activation and apoptosis in platelet concentrates collected by apheresis.
Procházková R; Andrýs C; Hubácková L; Krejsek J
Transfus Apher Sci; 2007 Oct; 37(2):115-23. PubMed ID: 17945536
[TBL] [Abstract][Full Text] [Related]
13. Quality analysis of blood components obtained by automated buffy-coat layer removal with a top & bottom system (Optipress (R)II).
Hurtado C; Bonanad S; Soler Mf; Mirabet V; Blasco I; Planelles Mf; De Miguel A
Haematologica; 2000 Apr; 85(4):390-5. PubMed ID: 10756365
[TBL] [Abstract][Full Text] [Related]
14. A critical comparison of platelet preparation methods.
Vassallo RR; Murphy S
Curr Opin Hematol; 2006 Sep; 13(5):323-30. PubMed ID: 16888436
[TBL] [Abstract][Full Text] [Related]
15. Pooled platelet concentrates: an alternative to single donor apheresis platelets?
Pietersz RN
Transfus Apher Sci; 2009 Oct; 41(2):115-9. PubMed ID: 19716340
[TBL] [Abstract][Full Text] [Related]
16. Preparation and pathogen inactivation of double dose buffy coat platelet products using the INTERCEPT blood system.
Abedi MR; Doverud AC
J Vis Exp; 2012 Dec; (70):e4414. PubMed ID: 23242463
[TBL] [Abstract][Full Text] [Related]
17. The effect of double- and triple-apheresis platelet product donation on apheresis donor platelet and white blood cell counts.
Richa E; Krueger P; Burgstaler EA; Bryant SC; Winters JL
Transfusion; 2008 Jul; 48(7):1325-32. PubMed ID: 18346017
[TBL] [Abstract][Full Text] [Related]
18. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
Seghatchian J; Hervig T; Putter JS
Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
[TBL] [Abstract][Full Text] [Related]
19. Prestorage leukocyte reduction of cellular blood components.
Dzik S
Transfus Sci; 1994 Jun; 15(2):131-9. PubMed ID: 10147358
[TBL] [Abstract][Full Text] [Related]
20. [Techniques of preparation and indications of labile blood products].
Clément S
Transfus Clin Biol; 2011 Apr; 18(2):250-61. PubMed ID: 21474355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
